{"id":1217,"date":"2024-03-05T16:17:31","date_gmt":"2024-03-05T16:17:31","guid":{"rendered":"https:\/\/www.asklepios-advisors.com\/?p=1217"},"modified":"2024-03-11T12:07:13","modified_gmt":"2024-03-11T12:07:13","slug":"visionhealth-raised-a-new-financing-round-to-extended-copd-and-asthma-study","status":"publish","type":"post","link":"https:\/\/www.asklepios-advisors.com\/index.php\/2024\/03\/05\/visionhealth-raised-a-new-financing-round-to-extended-copd-and-asthma-study\/","title":{"rendered":"VisionHealth raised a new financing round to extended COPD and asthma study"},"content":{"rendered":"\n

Munich, Germany – February 27th, 2023<\/em><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Proceeds willbe used to finance extended COPD and asthma study for market preparation
of Kata\u00ae, an innovative digital therapeutic for improved inhalation.
DB Speciality Invest, an investment firm of Dr. Dietrich Bruchmann, invests in VisionHealth.
Funds will be used for EU and U.S. regulatory approval and commercial launch of the Kata\u00ae
app in Germany and selected European markets.
VisionHealth GmbH, a pioneer in digital therapeutics (DTx) to enhance inhaled treatment of
chronic lung diseases, today announced the successful closing of a private financing round
led by DB Speciality Invest GmbH & Co. KG, Neu-Ulm, Germany. The investment firm is
owned by the successful life science entrepreneur Dr. Dietrich Bruchmann, founder and CEO
of Nuvisan Pharma Holding GmbH, a renowned and fully integrated Contract Research
Organization in Neu-Ulm. He will take a seat on the non-executive Board of VisionHealth.
The new funds will be used to finance a second, larger study, which will enable VisionHealth
to provide even stronger scientific evidence to decision makers and physicians when
evaluating their recommendation of the Kata\u00ae app, a class IIa medical device (CE, MDR). The
study is designed as a randomly controlled, multi-centric trial over the period of one year
with around 120 patients suffering from chronic respiratory diseases asthma or COPD.
Dr. Dietrich Bruchmann, founder and CEO of Nuvisan Pharma Holding Group, said: \u201cI am
eager to see the potential of Kata\u00ae unfold, as access for asthma and COPD patients improves.
Heading a CRO active in the respiratory field, I have also been intrigued by the application of
the Kata\u00ae Clinical app in clinical trials: Incorrect inhaled admission of therapeutics can be a
major error factor. Supporting each patient individually via the app on how to administer an
inhalator properly improves patient outcomes in everyday life and also the quality of clinical
trial results, ensuring maximum benefit from therapy.\u201d
Dr. Sabine Haeussermann, CEO and founder of VisionHealth, added: \u201cWe are excited to back
up the very positive proof of concept study results with more data on the efficiency of Kata\u00ae.
With over 2.400 users since the first release, a stunning 83.3\u202f% of users told us they would
like to continue using the Kata\u00ae App in the future; similar amounts of users would
recommend the app to friends with respiratory diseases. It is truly rewarding to see how we can make a difference for patients and improve health outcomes\u201d.<\/p>\n\n\n\n

Frederic Vincent & Dr. Edouard Gobitz, Managing Partners Asklepios Advisors, Healthcare
focused Investment Bank added: \u201cOur firm is delighted to have supported Vision Health in
such financing round. This transaction demonstrates Asklepios Advisors strong commitment
& innovative approach to supporting its clients in their next growth phase.\u201d
Asklepios Advisors served as Vision Health’s exclusive financial advisor.<\/p>\n","protected":false},"excerpt":{"rendered":"

Munich, Germany – February 27th, 2023 Proceeds willbe used to finance extended COPD and asthma study for market preparationof Kata\u00ae, an innovative digital therapeutic for improved inhalation.DB Speciality Invest, an investment firm of Dr. Dietrich Bruchmann, invests in VisionHealth.Funds will be used for EU and U.S. regulatory approval and commercial launch of the Kata\u00aeapp in […]<\/p>\n","protected":false},"author":1,"featured_media":1218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1217","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts\/1217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/comments?post=1217"}],"version-history":[{"count":3,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts\/1217\/revisions"}],"predecessor-version":[{"id":1445,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts\/1217\/revisions\/1445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/media\/1218"}],"wp:attachment":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/media?parent=1217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/categories?post=1217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/tags?post=1217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}